Clinical trials are research studies designed to test whether a medical intervention, treatment, or device is safe and effective. The success of clinical trials and the potential availability of new treatments for FH depend on the participation of individuals with familial hypercholesterolemia (FH), … Read More
Accelerating Family Screening with Genetic Testing Could Change Care for Familial Hypercholesterolemia
PASADENA, Calif., May 16, 2018 – The FH Foundation, a leading research and advocacy organization, today announced the launch of a new research study that aims to understand the willingness for … Read More
The FH Foundation is joining with Breakaway from Heart Disease at the 2018 Amgen Tour of California community events, to increase awareness of familial hypercholesterolemia (FH) and break the cycle of family heart disease. FH causes approximately 20% of heart attacks under the age of 45, and is the most … Read More
This Mother’s Day, I offer a gift to all the moms who want to be there for their children, and want their children to live long, healthy, lives free of heart disease and the heartache and loss it can cause.
This Mother’s Day I am asking everyone I know – Do you have a family history … Read More
Today, The FH Foundation, is pleased to recognize UnitedHealthcare for streamlining its prior authorization process and expanding access to PCSK9 inhibitors for familial hypercholesterolemia (FH). These changes are making it easier and faster for doctors and patients who qualify to get access to these … Read More
Katherine Wilemon, founder and CEO of the FH Foundation, talked with Daniel Levine of The Bio Report podcast, about familial hypercholesterolemia (FH). The episode highlights how FH is an invisible condition that causes high LDL-C cholesterol and increases the risk for early heart disease. Unfortunately, … Read More
The results of the ODYSSEY Outcomes trial of Alirocumab (Praluent) were presented today at the American College of Cardiology Scientific sessions. Alirocumab is an injectable antibody PCSK9 inhibitor that has been shown to significantly reduce LDL-cholesterol levels in prior trials.
ODYSSEY Background
ODYSSEY … Read More
For 30 years, we have had effective treatment to reduce the risk for early heart disease that has devastated FH families for generations. Yet, as a healthcare system, we have failed to ensure that individuals with familial hypercholesterolemia (FH) are properly diagnosed and treated.
In order to … Read More
In recognition of Heart Month, two FH Advocates for Awareness, hit the gym. But this time, not to work out but to spread awareness of familial hypercholesterolemia (FH). Gwynne and Mel spent the morning sharing information about FH with their fellow health club members in West Chester, PA.
As FH is … Read More
The FH Foundation is proud to share published research from a Patient Centered Outcomes Research Institute (PCORI)-funded project implemented by the University of Rochester, with the FH Foundation.
The new research published in Health Education Journal aimed to determine individual and group patient … Read More
